scholarly journals Systemic Lupus Erythematosus complicated by Neuromyelitis Optica (Devic’s Syndrome): case series from a single paediatric rheumatology centre

2011 ◽  
Vol 9 (S1) ◽  
Author(s):  
Despoina Maritsi ◽  
Muthana Al-Obadi ◽  
Sonia Melo-Gomes ◽  
Kjell Tullus ◽  
Clarissa A Pilkington
Lupus ◽  
2006 ◽  
Vol 15 (2) ◽  
pp. 107-109 ◽  
Author(s):  
C Jacobi ◽  
K Stingele ◽  
R Kretz ◽  
M Hartmann ◽  
B Storch-Hagenlocher ◽  
...  

Author(s):  
C. Lourenço de Medeiros ◽  
V.C. Colares Lessa ◽  
M.L. Rodrigues Prata ◽  
R. Prudêncio de Lemos ◽  
A. R. Monfredinho ◽  
...  

2019 ◽  
Vol 13 (4) ◽  
pp. 89-95 ◽  
Author(s):  
E. S. Vinogradova ◽  
A. P. Panova ◽  
N. M. Bulanov ◽  
P. I. Novikov ◽  
S. V. Moiseev

Neuromyelitis optica ((NMO), Devic's syndrome) is an immune-mediated inflammatory demyelinating disease characterized by transverse myelitis and optic neuritis. Determination of the level of antibodies to aquaporin 4 (NMO-IgG) is presently one of the key methods for the diagnosis and assessment of the activity of ONM, which allows this disease to be differentiated from multiple sclerosis and other demyelinating CNS lesions. ONM can occur not only as an independent disease, but also as a syndrome in different systemic diseases, such as: systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody-associated vasculitides, Sjögren's disease, etc. (up to 50–70%). In such situations, the clinician is always confronted with a question as whether the patient can have two rare autoimmune diseases or develop ONM as a systemic manifestation of rheumatic disease.The paper describes a clinical case of a young female patient with SLE concurrent with a CNS lesion, the manifestations of which corresponded to ONM. The patient had focal changes in the substance of the brain and spinal cord, as evidenced by magnetic resonance imaging, as well as high NMO-IgG titers. The development of ONM worsens SLE prognosis and requires active immunosuppressive therapy. The patient received three plasmapheresis sessions, ultrahigh-dose glucocorticoid and cyclophosphamide therapy, followed by replacement with azathioprine, causing a stable clinical and laboratory disease remission to be achieved.


Sign in / Sign up

Export Citation Format

Share Document